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Application of 3-iodothyronamine (3-T1AM) results in decreased body temperature and
body weight in rodents. The trace amine-associated receptor (TAAR) 1, a family A G protein-
coupled receptor, is a target of 3-T1AM. However, 3-T1AM effects still persist inmTaar1 knock-
out mice, which suggest so far unknown further receptor targets that are of physiological rele-
vance. TAAR5 is a highly conserved TAAR subtype among mammals and we here tested
TAAR5 as a potential 3-T1AM target. First, we investigated mouse Taar5 (mTaar5) expression
in several brain regions of the mouse in comparison to mTaar1. Secondly, to unravel the full
spectrum of signaling capacities, we examined the distinct Gs-, Gi/o-, G12/13-, Gq/11- and MAP
kinase-mediated signaling pathways of mouse and human TAAR5 under ligand-independent
conditions and after application of 3-T1AM.We found overlapping localization of mTaar1 and
mTaar5 in the amygdala and ventromedial hypothalamus of themouse brain. Second, the mu-
rine and human TAAR5 (hTAAR5) display significant basal activity in the Gq/11 pathway but
show differences in the basal activity in Gs andMAP kinase signaling. In contrast to mTaar5,
3-T1AM application at hTAAR5 resulted in significant reduction in basal IP3 formation and
MAP kinase signaling. In conclusion, our data suggest that the human TAAR5 is a target for 3-
T1AM, exhibiting inhibitory effects on IP3 formation and MAP kinase signaling pathways, but
does not mediate Gs signaling effects as observed for TAAR1. This study also indicates differ-
ences between TAAR5 orthologs with respect to their signaling profile. In consequence, 3-
T1AM-mediated effects may differ between rodents and humans.
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Introduction
The group of trace amine-associated receptors (TAAR) belongs to family A G protein-coupled
receptors (GPCRs) [1]. Human and rodent TAARs are expressed in a variety of tissues includ-
ing several brain regions, kidney, stomach, liver, pancreas, small intestine, pituitary, and leuko-
cytes [2–7]. In addition, it is suggested that TAARs, except for TAAR1, constitute a part of the
olfactory system in vertebrates [8–14].
One functional characteristic of TAARs is the high ligand promiscuity, as they can be acti-
vated by neurotransmitters [2,15–17], psycho-active drugs [16–19], volatile amines [8,13,20],
and trace amines [2,14,19]. In addition, the L-thyroxine-derived thyroid hormone metabolite
3-iodothyronamine (3-T1AM), circulating in nano-molar concentrations in human blood [21],
has previously been identified as an agonist for rat and mouse Taar1 (mTaar1) [22,23].
3-T1AM was traceable in pico- to nanomolar concentrations in human blood [21,24] and
3-T1AM uptake into a high quantity of tissues in rodents at nanomolar concentrations is reli-
ably ascertained, including brain [25–28]. It was shown that 3-T1AM reduces body tempera-
ture, thus opposing the effects of classical thyroid hormones [22,29]. Further data supported a
role of 3-T1AM in energy metabolism as its injection into Djungarian hamsters revealed a sig-
nificant decrease of body mass and changes from carbohydrate to lipid utilization [29]. In a re-
cent study, even a much lower dose of 10 mg/kg 3-T1AM (compared to 50 mg/kg), given over a
period of 8 days, had a significant influence on weight maintenance in obese mice [30]. Appli-
cation of 3-T1AM in mice resulted in hyperglycemia [31] associated with an increase of plasma
glucagon and an endogenous glucose production [32]. Further studies revealed that acute
intracerebroventricular (ICV), intra-arcuate nucleus or intraperitoneal administration of
3-T1AM induces dose-dependent orexigenic effects on feeding behavior in rodents [33,34]. In
addition, ICV administration of 3-T1AM improved memory and enhanced curiosity in mice
[35] and injection to the pre-optic region of male rats showed a modulation of sleep [36].
However, targetedmTaar1 gene disruption in mice did not result in significant changes in
body weight or temperature regulation [37] and the 3-T1AM-induced hypothermic effect is
maintained in these mice [38]. Moreover, the pharmacologically inhibitory effects of exoge-
nously administered 3-T1AM are rather pointing to a cAMP-repressing effect in contrast to the
observed stimulatory effect of 3-T1AM on cAMP formation for TAAR1 in vitro [22,23].
Such discrepancies indicate that TAAR1may be not the primary in vivomediator of 3-T1AM-
induced action.
We here hypothesize that another member of the TAAR group might be a target for
3-T1AM and, thereby, be responsible for the observed effects in vivo. We focused on TAAR5 as
an alternative 3-T1AM target, since both TAAR1 and TAAR5 are expressed in primates [39]
and TAAR5 is the most highly conserved TAAR subtype among all characterized mammalian
species investigated so far. Therefore, expression profiles of mouse Taar1 and Taar5 (mTaar1
and mTaar5) in the brain were investigated with a focus on brain regions that are known to be
involved in temperature regulation, like the ventromedial hypothalamus. To unravel the full
spectrum of signaling capacities, we examined the distinct Gs-, Gi/o-, G12/13-, Gq/11- and MAP
kinase-mediated signaling pathways of mouse and human TAAR5 (mTaar5, hTAAR5) under
ligand-independent conditions and after application of 3-T1AM. To decipher potential molec-
ular reasons of observed differences between signaling of mouse and human TAAR5 we also
created and tested chimeric subtype-receptors.
Effects of 3-T1AM on TAAR5
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Materials and Methods
Expression analysis of mTaar1 and mTaar5 by in situ hybridization
Mouse Taar1 and Taar5 were tested for potential overlapping expression in the brain by free
floating in situ hybridization histochemistry using digoxigenin (DIG)-labeled locked nucleic
acid (LNA) probes (Exiqon Inc, Woburn, MA). All studies were approved by and performed
according to the guidelines of the Institutional Animal Care and Use Committee (IACUC) of
the University of Cincinnati where the respective experiments were performed.
Wild type (WT) C57BL/6 mice were sacrificed by an intra-atrial perfusion with saline, fol-
lowed by a solution of 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) at 4°C. Brains
were then isolated and post-fixed in 4% paraformaldehyde for 16 hours. After equilibration for 48
hours in RNase free 30% sucrose in 0.1 M Tris-buffered saline, tissue was cut into 25 μm sections.
Sections of brain were washed successively with PBS, 0.2 M HCl, and incubated in 0.2% gly-
cin and then 0.1% Triton X-100. Free floating sections were then prehybridized in 1x prehy-
bridzation solution (Sigma Aldrich, St. Louis, MO) and 50% formamide (Sigma Aldrich,
St. Louis, MO) for 1 hour at 55°C on a rocking platform. For hybridization, brain sections were
incubated for 8 hours with 200 nM concentration of LNA probe in hybridization buffer (Sigma
Aldrich, St. Louis, MO) at 57°C. After stringent washing steps with decreasing concentrations
of saline-sodium citrate, samples were incubated with 1:500 diluted anti-DIG antibody (goat)
at 4°C overnight. In a next step, samples were washed with TRIS-Borate-EDTA-buffer (TBE)
and incubated with an avidin-biotin-peroxidase complex (ABC) for 1 hour at room tempera-
ture. For visualization of mTaar1, brain sections were stained with 3,3’-diaminobenzidine
(DAB) for 5 minutes. Sections were mounted on gelatin-coated glass slides, dried, dehydrated
through a graded ethanol series, cleared in xylene and cover-slipped for image collection by
light microscopy. mTaar5 samples were stained with anti-DIG antibody as described above,
followed by a Dy-Light 488 labeled secondary anti-goat IgG (Jackson ImmunoResearch Labo-
ratories, West Grove, PA). Images were collected by confocal microscopy (Zeiss confocal 710,
Carl Zeiss Microscopy GmbH, Jena, Germany).
Cloning of TAARs and construction of the hTAAR5 chimeras by site
directed mutagenesis
All full-length TAAR and control constructs were cloned into the eukaryotic expression vector
pcDps and N-terminally tagged with a hemagglutinin (5’ YPYDVPDYA 3’) epitope (HA) for
functional assays and determination of cell surface expression, using KpnI and SpeI restriction
sites. To enhance cell surface expression, hTAAR1 and hTAAR5 were N-terminally fused with
the first 21 amino acids of the bovine rhodopsin (Rho-tag) as previously described [8,20,40].
hTAAR5 chimeras were generated by exchanging 8 amino acids differing between human and
mouse receptors using site-directed mutagenesis. For each step, a PCR was performed using over-
lapping oligonucleotides containing the respective amino acid exchange. Mutagenesis was per-
formed based on the above described full-length hTAAR5 sequence, cloned into the eukaryotic
expression vector pcDps and N-terminally tagged with a hemagglutinin epitope and Rho-tag. All
plasmids were sequenced and verified with BigDye-terminator sequencing (PerkinElmer Inc., Wal-
tham, MA) using an automatic sequencer (ABI 3710 XL; Applied Biosystems, Foster City, CA).
Cell culture and transient transfection
For determination of signal transduction properties (cAMP, inositol trisphosphate (IP)-3-,
RhoA- and MAP kinase reporter gene assays), HEK293 cells (human embryonic kidney cells)
[41] (American Type Culture Collection, LGC Standards GmbH, Wesel, Germany) were
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cultured in Minimum Essential Medium Earle´s (MEM) (Biochrom AG, Berlin, Germany)
supplemented with 10% FBS (PAA Laboratories GmbH, Pasching, Austria), 100 U/mL penicil-
lin, 100 μg/mL streptomycin (Biochrom AG, Berlin, Germany) and 2 mM L-glutamine (Invi-
trogen, Carlsbad, CA) at 37°C with 5% CO2.
Cell surface expression studies were conducted in COS-7 cells (African GreenMonkey
SV40-transfected kidney fibroblast cell line) [42] (American Type Culture Collection, LGC
Standards GmbH,Wesel, Germany), which are more robust facing the numerous washing steps.
COS-7 cells were cultured in Dulbecco´s Modified Eagle Medium (DMEM) (Biochrom AG,
Berlin, Germany) supplemented identically as MEM. Transient transfection was performed in
the respective supplement-free medium and media were changed 16 hours after transfection. For
obtaining mock data, cells were transiently transfected with the empty vector pcDps.
For cAMP accumulation assays, HEK293 cells were cultured in 48 well plates (3.75 x 104
cells/well), and transiently transfected with 83 ng DNA using 0.9 μL Metafectene (Biontex, Mu-
nich, Germany) per well, 24 hours after seeding.
For reporter gene assays (G12/13, MAP kinase and IP3), HEK293 cells were seeded in 96-well
plates (1.5 x 104 cells/well) or 48-well plates (3.75 x 104 cells/well, for pertussis toxin (PTX) sen-
sitivity experiments). 28 hours post-seeding, receptor DNA was co-transfected with the respec-
tive reporter construct (Promega, Fitchburg, WI), using 0.9 μL Metafectene and a total amount
of 167 ng DNA in equal ratios per well.
For internalization studies, COS-7 cells were seeded in 48 well plates (3.75 x 104 cells/well)
and transiently transfected with 167 ng DNA using 1 μL Metafectene per well.
Ligands were purchased from Sigma Aldrich (St. Louis, MO). 3-T1AM was purchased from
Santa Cruz Biotechnology (Dallas, Texas).
Determination of cell surface expression
To determine ligand-induced internalization and cell surface expression of the chimeric
hTAAR5, a cell surface ELISA (enzyme-linked immunosorbent assay) was performed. There-
fore, cells were transiently transfected with N-terminally HA-tagged receptors. For internaliza-
tion studies, cells were additionally stimulated for six hours with 10 μM 3-T1AM [22], 72 hours
post-transfection. For samples at time point zero, incubation media were immediately replaced
and cells fixed with 4% paraformaldehyde and blocked with 10% FBS overnight.
Cells were probed with a biotin labeled Anti-HA antibody (Roche, Basel, Switzerland)
(1:200) and detected with horseradish peroxidase-labeled Streptavidin (BioLegend, London,
UK) (1:2,500). Color reaction was achieved by adding the substrate o-phenylendiamine (Sigma
Aldrich, St. Louis, MO) solved in a buffer composed of 0.1 M citric acid and 0.1 M sodium hy-
drogen-phosphate enriched with hydrogen peroxide. Reaction was stopped with sodium sul-
fite-oversaturated 1 M hydrogen chloride. Absorption was measured at 492 / 620 nm by using
Anthos Reader 2001 (Anthos Labtech Instruments, Salzburg, Austria).
Determination of Gs and Gi/o activation by cAMP accumulation assays
Gs and Gi/o signaling were measured by a competitive cAMP accumulation assay based on the
AlphaScreen technology (Perkin-Elmer Life Science, Boston, MA). Stimulation was performed
in stimulation buffer composed of MEM and 1 mM 3-isobutyl-1-methylxanthine (IBMX,
Sigma Aldrich, St. Louis, MO) as phosphodiesterase inhibitor, 40 hours post-transfection.
For measurement of Gs activation, HEK293 cells were incubated for 45 minutes with 10 μM
3-T1AM and/or 100 μM dimethylethylamine (DMEA, Sigma Aldrich, St. Louis, MO). mTaar1
stimulated with 3-T1AM and mTaar5 stimulated with DMEA served as positive assay controls
with less elaborate handling compared to other known mTaar5 agonists [20,22]. For Gi/o
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signaling analysis, cells were co-stimulated with 50 μM forskolin (AppliChem GmbH, Darm-
stadt, Germany) to stimulate the overall adenylyl cyclase. Basal Gi/o activity of TAAR was
determined in comparison to FSK-stimulated mock transfection.
Stimulation was performed in triplicates at 37°C with 5% CO2 saturated air and was stopped
by aspirating the medium. Cells were then lysed for 1.5 hours at 4°C on a shaking platform
with cell lysis buffer containing 5 mMHEPES, 0.1% BSA, 0.3% Tween 20, and 1 mM IBMX
(pH 7.4). Intracellular cAMP accumulation was determined according to the manufacturers‘
protocol and as previously described [43].
Determination of G12/13, Gq/11 and MAP kinase activation via luciferase
reporter gene assay
G12/13, MAP kinase (MAPK) and Gq11/phospholipase C (Gq/11) signaling were measured via a
luciferase reporter gene assay (G12/13: RhoA-luc; MAPK: SRE-luc; Gq/11: IP3-luc) (Promega,
Fitchburg, WI). For measurement of G12/13 signaling (RhoA-luc), cells were co-transfected with
a reporter construct containing the firefly luciferase gene under the control of a serum response
factor response element (SRF-RE) (pGL4.34) and either the receptor construct or the empty
vector plasmid DNA. Transcription of luciferase reporter gene is activated in response to
RhoA GTPase activation. For indirect measurement of the MAP kinase pathways (SRE-luc),
cells were co-transfected with a reporter construct containing the firefly luciferase reporter
gene and a serum response element (SRE) (pGL4.33), and either receptor or empty vector plas-
mid DNA. SRE drives the transcription of luciferase reporter gene in response to activation of
MAP kinase signaling pathway. For measurement of Gq/11 signaling pathway (IP3-luc), cells
were co-transfected with the nuclear factor of activated T-cells (NFAT) DNA (pGL4.30), a re-
porter construct containing the firefly luciferase gene under the control of the NFAT response
element (NFAT-RE), and either receptor or empty vector plasmid DNA. Transcription of lucif-
erase is driven by NFAT-RE in response to IP3 formation.
To discriminate between PTX-sensitive and PTX-insensitive basal signaling, transiently
transfected cells were incubated with 500 nM PTX, 20 hours prior to ligand stimulation. Sup-
plement-free MEM was added to the untreated cells.
Two days post-transfection, cells were washed with PBS (Biochrom AG, Berlin, Germany)
and stimulated for 6 hours with 10 μM 3-T1AM and/or 100 μMDMEA in supplement-free
MEM at 37°C with 5% CO2 air. Reactions were terminated by aspirating the medium.
Cells were lysed for 15 minutes on a shaking platform at room temperature, using 1x passive
lysis buffer (Promega, Fitchburg, WI). Measurement was conducted with automatic luciferase
substrate injection of 40 μL in a black 96 well plate using a Berthold Microplate Reader (Bert-
hold Technologies GmbH & Co KG, Bad Wildbad, Germany).
Data analysis
Basal state is shown as fold over basal mock transfection, and stimulation is referred to fold
over ligand-stimulated mock with the respective substance to omit endogenous effects. Bar
graphs and concentration-response curve with mean ± SEM as well as statistical analyses were
generated using GraphPad Prism Version 6.0 (GraphPad Software, San Diego, CA).
Results
Overlapping tissue expression of mTaar5 and mTaar1 in mouse brain
mTaar5 expression has been demonstrated in the olfactory epithelium [8,11,44]. Because it is
well known that distinct areas in the hypothalamus are important for temperature and body
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weight regulation [45–47] we analyzed the expression of mTaar1 and mTaar5 in distinct hypo-
thalamic regions. We performed in situ hybridization with double DIG-labeled LNA probes on
mouse brain sections to achieve high specificity and sensitivity with minimal risk for genomic
DNA contamination. A scrambled nonsense LNA probe served as negative control for the re-
spective tissue sections showing no specific signals (Fig. 1 A, C, E, G, I, L).
Signals specific for mTaar5 were detected in the arcuate nucleus (ARC) (Fig. 1B), the ven-
tromedial hypothalamus (VMH) (Fig. 1D), and the amygdala (Fig. 1F). No mTaar5 expression
was observed in any other hypothalamic region. Expression of mTaar1 was detected in the
VMH (Fig. 1K) and the amygdala (Fig. 1M) of mouse brain but not in the ARC (Fig. 1H). Our
data indicate overlapping expression of mTaar5 and mTaar1 in the VMH and the amygdala.
Mouse Taar5 but not hTAAR5 shows basal Gs-mediated signaling
To analyze signal transduction properties of mTaar5 and hTAAR5, both orthologs were ex-
pressed in HEK293 cells and showed comparable cell surface expression levels in ELISA
(Fig. 2A).
As already reported [8,20,48], mTaar5 displayed basal activity in the Gs/adenylyl cyclase
pathway (Gs) (Table 1, Fig. 2B). In contrast, hTAAR5 revealed no significant basal activity in
the cAMP assay (Fig. 2B). DMEA (100 μM) induced a robust cAMP signal via mTaar5 but not
via hTAAR5 (Table 1, Fig. 2B). This indicates significant species-specific differences in
TAAR5 signaling.
Fig 1. Expression of mTaar1 andmTaar5 in various murine brain regions. Transcript expression studies were analyzed by in situ hybridization using a
LNA (locked nucleic acid) probe. C57BL/6 mouse brains were sectioned and treated with the corresponding LNA probes. Signals were visualized by an
avidin-biotin complex using DY-light 488 streptavidin (A-F) or DAB (3,3’-diaminobenzidin) staining (G-M). III = third ventricle; OT = optical tract; DY-light 488
streptavidin labeled samples are shown with a 40-fold, DAB stained sections are depicted with a 20-fold magnification. Bar scale in (B) equals 100 μm, bar
scale in (K) equals 200 μm. (A-F): mTaar5 expression; (A), (C) and (E) represent negative controls using a scrambled LNA probe showing homogenous
staining. (B), (D) and (F) show expression of mTaar5 in arcuate nucleus (ARC), in ventromedial hypothalamus (VMH) and amygdala, respectively. (G-M):
mTaar1 expression, the brain regions of interest are highlighted by circles. (G), (I) and (L) represent negative controls using a scrambled LNA probe. (K) and
(M) show expression of mTaar1 in mice brains in VMH and amygdala, respectively. (H) No expression could be detected in the ARC.
doi:10.1371/journal.pone.0117774.g001
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PLOSONE | DOI:10.1371/journal.pone.0117774 February 23, 2015 6 / 19
HEK293 cells expressing hTAAR5 or mTaar5 were stimulated with either 10 μM 3-T1AM
or 100 μMDMEA. Values indicate cAMP accumulation or luciferase activity (IP3-luc, RhoA-
luc, SRE-luc), and are depicted as mean ± SEM fold over basal or ligand-stimulated mock.
Treatment with DMEA, serving as assay control in Gs signaling, showed a stimulation of about
8-fold over basal for mTaar5 but not for hTAAR5. For Gq/11 signaling, the basal activity of
hTAAR5 and mTaar5 are statistically significant (p 0.001) compared to mock transfec-
tion (original data of hTAAR5: 19489 ± 2925 RLU; mTaar5: 33396 ± 1434; vs. mock transfec-
tion: 5809 ± 859 RLU, respectively). For Gs signaling, the increased basal value of hTAAR1 is
statistically significant (p 0.001) but not for hTAAR5 compared to mock transfection
Fig 2. Functional characterization of mouse and human TAAR5 in cAMP and IP3 assays. (A) Cell surface expression was tested using an ELISA.
Mouse and human TAAR5 were N-terminally HA-tagged and transiently transfected with COS-7 cells. Results are depicted as mean ± SEM obtained from 3
independent assays measured in 4 replicates. Data are presented as fold over mock transfection. An unpaired two-tailed t-test was performed which showed
no significant difference of cell surface expression between both receptor orthologs. (B) HEK293 cells expressing mouse or human TAAR5 were stimulated
with 100 μMDMEA. The cAMP accumulation was measured by competitive cAMP assay based on AlphaScreen technology. Results are depicted as either
fold over basal mock or fold over DMEA stimulated mock transfection. Data are shown as mean ± SEM from n 3 independent experiments with 3 or more
replicates. Statistical analyses were carried out with an unpaired two-tailedWelch-corrected t-test; ***p 0.001, compared to the respective basal activity.
(C) HEK293 cells transiently expressing hTAAR5 or mTaar5 were incubated with or without 500 nM pertussis toxin (PTX), 20 hours prior to measurement.
Supplement-free MEMwas added to the untreated cell. IP3-luc levels were determined without (basal) and with PTX treatment. Results are presented as
relative light units (RLU). Data were obtained from 3 to 6 independent experiments measured in triplicates and are shown as mean ± SEM. An unpaired two-
tailed Welsh-corrected t-test was used for statistical analyses; *p 0.05; **p 0.01; ***p 0.001. Human TAAR5 shows elevated basal IP3-luc activity,
which was maintained after treatment with PTX pointing to a basal Gq/11 activity. Basal IP3-luc activity of mTaar5 was not significantly influenced by
PTX treatment.
doi:10.1371/journal.pone.0117774.g002
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(original data of hTAAR1: 3 ± 0.6 nM cAMP; hTAAR5 0.6 ± 0.2 nM cAMP; vs. mock transfec-
tion: 0.3 ± 0.08 nM cAMP, respectively). Furthermore, mTaar5 showed elevated, but not signif-
icant basal values in the Gs signaling pathway compared to mock transfection (p = 0.1 with raw
values of mock 1.2 ± 0.4 nM cAMP and mTaar5 3.1 ± 1.0 nM cAMP). Both TAAR5 orthologs
showed elevated basal activity in the SRE reporter assay (MAPK signaling). Results of statistical
analyses with stimulated value compared to basal value of the respective TAAR are shown anal-
ogously to the figures. Unpaired two-tailed Welsh-corrected t-tests were performed; p 0.05;
p 0.01; p 0.001.
Next, we unraveled the signal transduction pathway for hTAAR5 and tested Gq/11 via a re-
porter gene assay (IP3-luc). Interestingly, we found high basal activity for both hTAAR5 and
mTaar5 (Figs. 2C, 3B, Table 1). This basal activity was pertussis toxin (PTX)-insensitive
(Fig. 2C). Furthermore, neither basal activity of the Gi/o adenylyl cyclase (Gi/o) nor of the G12/13
signaling was detected (Table 1).
3-T1AM decreases basal IP3 level of hTAAR5
3-T1AM acts as an agonist at rat Taar1 [22] and also hTAAR1 (Fig. 3A). In contrast, concentra-
tions ranging from 10–5 M to 10–7 M 3-T1AM did not induce cAMP accumulation in HEK293
cells transfected with hTAAR5 or mTaar5 (Table 1).
Next, we tested whether 3-T1AM exerts effects on IP3 signaling. Unexpectedly, 3-T1AM sig-
nificantly reduced basal IP3 formation to ~70% of the signal obtained for non-treated cells
(Fig. 3B). This decrease of basal IP3 formation was concentration-dependent with an EC50
value of 4.4 ± 0.9 μM (Fig. 3C).
Using an indirect measure of the MAP kinase pathway activation, we co-transfected hTAAR5
or mTaar5 with an SRE reporter construct. Both TAAR5 orthologs showed increased basal activi-
ty in the SRE reporter assay (Fig. 3D, Table 1). Similar to the data observed for IP3 formation,
3-T1AM application resulted in a robust reduction of signaling in hTAAR5 but not in mTaar5
transfected cells (Fig. 3D). These findings point to an inverse agonistic effect of 3-T1AM at
hTAAR5. Moreover, DMEA showed an inverse agonistic effect in the Gq/11 pathway on mTaar5,
but not on hTAAR5 (S1 Fig.). Co-treatment of DMEA and 3-T1AM at hTAAR5 revealed no ef-
fect of DMEA on the 3-T1AM-induced basal signalling inhibition. On the other hand, 3-T1AM
did not modulate the inverse agonistic action of DME at mTaar5 (S1 Fig.).
To ensure that the signal reduction after 3-T1AM incubation is not due to internalization of
the receptor, we investigated cell surface expression following 3-T1AM incubation for 6 hours.
As shown in Fig. 3E, 3-T1AM treatment had no significant influence on hTAAR5 cell
surface expression.
In summary, our data indicate profound differences between mTaar5 and hTAAR5, specifi-
cally in basal signaling properties, DMEA-induced cAMP accumulation, and 3-T1AM-modi-
fied basal activities.
Substitutions of mTaar5-specific amino acids in hTAAR5
To unravel the molecular details of these species-specific differences of TAAR function, we
generated chimeric receptors based on differences in the amino acid sequence of both recep-
tors. For this purpose an amino acid sequence alignment was used to predict residues that are
potentially involved in ligand binding and signaling (for detailed substitutions see Table 2, and
Figs. 4, 5). These specific residues were substituted in three multiple combinations from
mTaar5 into corresponding positions of hTAAR5. In total, six single mutations were substitut-
ed at corresponding positions, three located in the extracellular loop ECL2 and three in the in-
tracellular loop ICL3 (Table 2 and Fig. 5).
Effects of 3-T1AM on TAAR5
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Our experiments demonstrate that none of the combined substitutions transfers the known
cAMP signaling properties from murine to human TAAR5 (Fig. 6A), with respect to the high
basal activity or the capacity to induce cAMP accumulation by DMEA. The increased basal
cAMP accumulation and ligand induced stimulation by DMEA at mTaar5 was not observed
for any chimeric construct, including a full six amino-acid substitution that combines both all
extra- and intracellular substitutions (Table 2, chim3). Furthermore, the constructs were
tested in the MAPK signaling pathways due to higher signal ratios compared to the back-
ground. In this SRE-reporter assay, each modification at hTAAR5 including the minimal





basal signaling [fold over basal
mock]
ligand ligand stimulated signaling [fold over
stimulated mock]
hTAAR1 cAMP level 13.3 ± 5.1 3-T1AM
(10 μM)
204.4 ± 25.2 **
hTAAR5 cAMP level 1.9 ± 0.9 3-T1AM
(10 μM)
0.7 ± 0.2
IP3-luc 3.6 ± 0.2 3-T1AM
(10 μM)
2.7 ± 0.2 **
cAMP inhibition 1.0± 0.1 3-T1AM
(10 μM)
1.0 ± 0.2
SRE-luc 6.2 ± 0.8 3-T1AM
(10 μM)
4.0 ± 0.6 *
RhoA-luc 1.6 ± 0.2 3-T1AM
(10 μM)
1.4 ± 0.1
mTaar5 cAMP level 2.2 ± 0.8 3-T1AM
(10 μM)
3.5 ± 1.8
IP3-luc 3.5 ± 0.3 3-T1AM
(10 μM)
3.5 ± 0.4
cAMP inhibition 1.9 ± 0.2 3-T1AM
(10 μM)
1.7 ± 0.1
SRE-luc 3.1 ± 0.4 3-T1AM
(10 μM)
2.5 ± 0.5
RhoA-luc 1.6 ± 0.1 3-T1AM
(10 μM)
1.3 ± 0.1
hTAAR5 cAMP level 1.2 ± 0.01 DMEA
(100 μM)
1.4 ± 0.1
mTaar5 cAMP level 2.9 ± 0.5 DMEA
(100 μM)
25.4 ± 3.2 ***
HEK293 cells expressing hTAAR5 or mTaar5 were stimulated with either 10 μM 3-T1AM or 100 μM DMEA. Values indicate cAMP accumulation or
luciferase activity (IP3-luc, RhoA-luc, SRE-luc), and are depicted as mean ± SEM fold over basal or ligand-stimulated mock. Treatment with DMEA,
serving as assay control in Gs signaling, showed a stimulation of about 8-fold over basal for mTaar5 but not for hTAAR5. For Gq/11 signaling, the basal
activity of hTAAR5 and mTaar5 are statistically signiﬁcant (***p â¤ 0.001) compared to mock transfection (original data of hTAAR5: 19489 ± 2925 RLU;
mTaar5: 33396 ± 1434; vs. mock transfection: 5809 ± 859 RLU, respectively). For Gs signaling, the increased basal value of hTAAR1 is statistically
signiﬁcant (***p  0.001) but not for hTAAR5 compared to mock transfection (original data of hTAAR1: 3 ± 0.6 nM cAMP; hTAAR5 0.6 ± 0.2 nM cAMP;
vs. mock transfection: 0.3 ± 0.08 nM cAMP, respectively). Furthermore, mTaar5 showed elevated, but not signiﬁcant basal values in the Gs signaling
pathway compared to mock transfection (p = 0.1 with raw values of mock 1.2 ± 0.4 nM cAMP and mTaar5 3.1 ± 1.0 nM cAMP). Both TAAR5 orthologs
showed elevated basal activity in the SRE reporter assay (MAPK signaling). Results of statistical analyses with stimulated value compared to basal value
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Fig 3. Signaling parameters of human andmurine TAAR5 after treatment with 3-T1AM. (A) HEK293 cells expressing human TAAR1 were stimulated
with 10 μM 3-T1AM. For Gs signal determination cAMP accumulation was measured. Results are depicted as fold over basal mock or fold over 3-T1AM-
stimulated mock. Data is shown as mean ± SEM from n 3 independent experiments with 3 or more replicates. 3-T1AM is a potent agonist for hTAAR1
(**p< 0.01). Statistical analysis was carried out with an unpaired two-tailedWelch-corrected t-test. (B) HEK293 cells transiently expressing hTAAR5 or
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multiple-mutants with three side chain substitutions led to a decreased basal SRE activity
(Fig. 6B). The decrease of SRE-luc signaling after application of 3-T1AM as observed for
hTAAR5 was consequently also abolished at the chimeric receptors with the lowered basal
activity.
Discussion
The main objective of this study was the characterization of TAAR5 as a potential receptor tar-
get for 3-T1AM that might account for 3-T1AM-mediated physiological effects. In this study,
we tested whether TAAR5 stimulation by the putative ligand 3-T1AM and the known agonist
DMEA activate distinct signaling pathways via Gs, Gi/o, G12/13 and Gq/11 coupling as well as
MAP kinase pathway activation.
Co-expression of mTaar1 and mTaar5 in brain regions
First of all, we demonstrated that mTaar5 is expressed in specific regions in the brain that are
responsible for weight regulation as well as for the control of body temperature [45–47] like the
VMH. As several studies indicate that AMP-activated protein kinase (AMPK) in the VMH
plays a role in thermogenesis of brown adipose tissue, we speculated that activation of mTaar5
might, therefore, explain the observed effect on body temperature after 3-T1AM application in
wild type and mTaar1 deficient mice [45,46,49].
It is commonly accepted that TAARs represent a second class of olfactory receptors in the
olfactory epithelium of vertebrates [8–14]. Except for TAAR1, all TAAR subtypes are expressed
in the olfactory epithelium with TAAR5 exhibiting the highest expression levels. TAARs are
hypothesized to be pheromone receptors even in humans, but the mTaar5 is still more sensitive
to volatile amines than its human orthologe [44].
mTaar5 were stimulated with 10 μM 3-T1AM and IP3-luc levels were determined. Results are presented as either fold over basal mock transfection for basal
value or fold over 3-T1AM stimulated mock. An unpaired two-tailedWelsh-corrected t-test was used for statistical analyses, **p 0.01. Data are obtained
from 3 to 6 independent experiments measured in at least triplicates and are shown as mean ± SEM. (C) Human TAAR5 was stimulated with 3-T1AM
concentrations ranging from 1 nM to 100 μM. The concentration-dependent IP3-luc signaling curve indicated the inverse agonism of 3-T1AM at hTAAR5 with
an EC50 value of 4.4 ± 0.9 μM. (D)MAP kinase activation was determined by luciferase activity in a luciferase reporter gene assay (SRE-luc). HEK293 cells
were co-transfected with a reporter construct containing a serum response element linked to the firefly luciferase reporter gene and in combination with the
different receptor constructs, respectively. Cells were stimulated with 10 μM 3-T1AM and SRE-luc levels were determined. Results are presented as
mean ± SEM as either fold over basal mock transfection for basal value or fold over 3-T1AM-stimulated mock. An unpaired two-tailed Welsh-corrected t-test
was performed for statistical analyses; *p 0.05. (E) Cell surface expression studies of hTAAR5 were conducted in COS-7 cells for 6 hours after stimulation
with or without 10 μM 3-T1AM using an ELISA. Results are depicted as mean ± SEM obtained from 3 independent assays measured in 4 replicates. Data are
presented as fold over basal hTAAR5. An unpaired two-tailed t-test with Welch-correction was performed.
doi:10.1371/journal.pone.0117774.g003
Table 2. Overview of the amino acid substitutions between human andmice for construction of chimeric TAAR5.
Construct Substitution
extracellular intracellular
chim1 T177R R178A L196F
chim2 T234R K238Q H246R
chim3 T177R R178A L196F T234R K238Q H246R
Based on an amino acid sequence alignment between mouse and human TAAR5, the six residues depicted here (see also Fig. 5) from mTaar5 were
identiﬁed to be species-speciﬁc and potentially involved in binding and signaling capacities. They were ﬁnally substituted in three multiple combinations
from mTaar5 into corresponding positions of hTAAR5, subdivided into mutations at the extra- and intracellular site. Combinations of multiple-mutations
were designed to unravel potential effects that are dependent on simultaneous modiﬁcations at both receptor sites.
doi:10.1371/journal.pone.0117774.t002
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3-T1AM acts as inverse agonist at hTAAR5
We observed that both hTAAR5 and mTaar5 show agonist-independent IP3 signaling, and this
activity is not blocked by PTX treatment (Fig. 2C). Notably, for the first time, inverse agonism
of 3-T1AM at hTAAR5 was demonstrated, since basal IP3 signaling of hTAAR5 is reduced
after 3-T1AM application (Fig. 3B). Inverse agonism is a well-known mechanism of ligand ac-
tion observed for constitutively active receptors [50] and has great therapeutic significance as a
variety of clinically used drugs like β-blockers [51] and anti-allergic drugs targeting the hista-
mine H1 receptor [52] act as inverse agonists [53,54]. The potential antidepressant S32212
showed inverse agonistic action at the serotonin receptor 2C in reducing basal IP3 production
mediated via Gq/11 activation [55].
Differences in signaling properties of mTaar5 and hTAAR5
Our experiments on possible signaling pathways of TAAR5 after application of 3-T1AM re-
vealed different signaling properties between mTaar5 and hTAAR5 since 3-T1AM shows in-
verse agonistic action at hTAAR5 in IP3 and MAP kinase activation but not at mTaar5
(Table 1, Fig. 3B, 3D). Additionally, we confirmed the volatile amine DMEA as an agonist for
mTaar5 [8,20], but not for hTAAR5 (Fig. 2B), however we cannot rule out that other ligands
like trimethylamine might activate Gs signalling [44]. A possible difference in ligand specificity
between hTAAR5 and mTaar5 was already suggested by previous studies [44]. Additionally,
DMEA might weakly bind to hTAAR5 in the 3-T1AM-induced signaling state as revealed by
co-stimulation studies, while 3-T1AM has no modulatory effect on DMEA induced inverse ag-
onistic action on mTaar5 (S1 Fig.).
The increased receptor activity in Gs pathway for mTaar5 might be explained by the fact
that the mouse receptor is less constrained, which results in a certain pre-activation (basal sig-
naling). The basally active conformation should have a higher affinity for the agonistic DMEA,
which led to a simplified shift towards the activated receptor proportions (lowered energetic
barrier), and this facilitates receptor activation by DMEA. hTAAR5 does not show a basal
cAMP activity which likely impedes activation of Gs by this receptor compared to mTaar5.
Fig 4. Partial sequence alignment between TAAR5 subspecies. This alignment compares amino acids of different TAAR subspecies in a region between
transmembrane helix (TMH) 4 and TMH6. Particular background colors indicating biophysical properties of the amino acid side chains: black—proline, blue—
positively charged, cyan/green—aromatic and hydrophobic, green—hydrophobic, red—negatively charged, gray—hydrophilic, dark-red—cysteines, magenta—
histidine. The putative helix dimensions and loop regions are assigned according to observable properties in the crystal structure of the inactivated β2-adrenergic
receptor conformation (pdb entry code 2RH1). Furthermore, in homology to the ligand binding regions of β-adrenergic receptors, amino acid positions covering
the putative ligand binding region of TAARs are marked with a plus (+) (see also [43]). Divergent residues between mouse and human TAAR5 participating
either in forming the potential extracellular ligand binding site or the intracellular effector binding region are indicated by ‘ = ’. These residues were suggest in this
study for substitutions between mouse and human TAAR5 and were also visualized on the structural model in Fig. 5. The overall identity between human and
mouse amino acid sequence is 87% (Blossum62 identity matrix). For alignment visualization the program BioEditwas used.
doi:10.1371/journal.pone.0117774.g004
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Fig 5. Structural homologymodel of hTAAR5 with highlighted amino acid positions that were
substituted to design chimeric human-murine receptors. The design of a structural homology model of
hTAAR5 was already reported [43]. We used this 3D information to visualize the amino acids differing
between human and mice TAAR5 in accordance to observed differences in the sequence of both species
(Fig. 4) with a focus on residues that are in spatial proximity to the extracellular ligand binding part or the
intracellular effector binding region. The human wild type amino acids (shown by atom spheres) and the
equivalent residues in mouse are provided as mutations in the labels. H1–7 = seven-transmembrane helices
1–7; H8 = eighth intracellular helix; ECL = extracellular loop, ICL = intracellular loop, Ntt = N-terminal tail;
Ctt = C-terminal tail.
doi:10.1371/journal.pone.0117774.g005
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Fig 6. MAP kinase activation and Gs signaling parameters of wild type TAAR5 and chimeric receptors.
(A) HEK293 cells expressing mouse or human TAAR5 or chimeric receptors (see Table 2 for details) were
stimulated with 100 μMDMEA. The cAMP accumulation was measured by competitive cAMP assay based
on AlphaScreen technology. Results are depicted as either fold over basal mock or fold over DMEA
stimulated mock transfection. Data are shown as mean ± SEM from n 3 independent experiments with
three or more replicates. Statistical analyses were carried out with an unpaired two-tailedWelch-corrected t-
test; ***p 0.001, compared to the respective basal activity. (B)MAP kinase activation was reported by
luciferase activity in a luciferase reporter gene assay (SRE-luc). HEK293 cells were co-transfected with a
reporter construct containing a serum response element and the firefly luciferase reporter gene, and the
different receptor constructs. Cells were stimulated with 10 μM 3-T1AM and SRE-luc levels were determined.
Results are presented as mean ± SEM as either fold over basal mock transfection for basal value or fold over
3-T1AM-stimulated mock. An unpaired two-tailed Welsh-corrected t-test was performed for statistical
analyses; *p 0.05.
doi:10.1371/journal.pone.0117774.g006
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However, both mouse and human TAAR5 show basal activities for Gq/11 and MAP kinase
signaling which points also to similarities in their pharmacological properties (Table 1). The
main difference can be described by the basal activity for Gs signaling (only at mTaar5) and the
higher MAP kinase signaling at hTAAR5 compared to mTaar5. Our studies on chimeric recep-
tors revealed that details in the amino acid constitution (ECL2 and ICL3) and interactions at
the extra- and intracellular sites likely contribute to the determination and fine-tuning of basal
activities, probably by regulation of conformational differences.
Conclusion
Our findings may imply that data obtained from mouse experiments are not simply transfer-
able to humans, or vice versa, at least for TAAR5. Consequently, one should take into consider-
ation that compounds tested in mouse models might have different, undesired, or even lack
effects in humans. This is even more important considering that 3-T1AM is currently qualified
as promising neuro- and cardio-protective compound against tissue injury after a stroke or a
heart attack because of its extensive and rapid effects on body temperature in rodents [56,57].
Testing 3-T1AM-mediated effects on other TAAR subtypes or related GPCR will help to fur-
ther decipher whether these effects are restricted to TAAR1 and hTAAR5. Whether 3-T1AM
also couples to other receptors than TAARs may be analyzed by an independent series of sys-
tematic binding and signaling studies.
We present evidence for inverse agonistic action of hTAAR5 but not mTaar5 after 3-T1AM
stimulation in our in vitro experiments. Based on these results, we propose that mTaar5 may
not be involved in known 3-T1AM-induced pharmacological or physiological effects in vivo,
since mTaar5 lacks any stimulating signaling properties after 3- T1AM application in vitro.
However, one cannot rule out that mTaar5 might act differently in vivo compared to in vitro or
that the observed pharmacological effects are mediated by other signaling pathways activated
by locally elevated cAMP levels. It might be possible that, in vivo, TAAR5 forms hetero-oligo-
mers with other receptors and thereby induces G-protein dependent signaling. Another possi-
bility, for the in vivo situation, is that 3-T1AM has merely a modulatory effect on receptor
signaling induced by other, so far not tested potential ligands of TAAR5. Thyronamines are
thought to interact with the adrenergic system [58,59], as 3-T1AM also binds to the alpha2A
adrenergic receptor [31]. It is also important to consider that the specificity for a respective G
protein is influenced by several parameters such as i. agonist concentration, ii. expression level
of the receptor [60,61], or iii. the cell type [62,63]. Further studies are necessary to reveal a
more complete spectrum of 3-T1AM-induced signaling. TAARs are suggested to interfere with
neurological disorders such as Parkinson´s disease, schizophrenia or Alzheimer´s disease [64].
Therefore, unraveling the full spectrum of evoked signaling effects of TAARs is a prerequisite
for the development of specific and selective ligands as future treatment option.
Supporting Information
S1 Fig. DMEA is an inverse agonist on mTaar5 but not on hTAAR5.HEK293 cells tran-
siently expressing hTAAR5 or mTaar5 were incubated without ligand or 10 μM 3-T1AM and/
or 100 μMDMEA. Results are presented as relative light units (RLU). Data were obtained from
3 to 6 independent experiments measured in triplicates and are shown as mean ± SEM. An un-
paired two-tailed Welsh-corrected t-test was used for statistical analyses; p 0.05; p 0.01;
p 0.001.
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